SkinBioTherapeutics Reports Strong Half-Year Growth and Prepares for Major Product Launch

SkinBioTherapeutics ( (GB:SBTX) ) has issued an update.

SkinBioTherapeutics has reported significant revenue growth for the half-year ending December 2024, driven by acquisitions and increased sales of its AxisBiotix product. The company completed the integration of Dermatonics and Bio-Tech Solutions, which contributed to its strengthened financial position. The upcoming global launch of its SkinBiotix lysate by Croda is anticipated to further enhance its market presence. The company is focused on expanding its product offerings and enhancing its operational capabilities, positioning itself for future profitability.

More about SkinBioTherapeutics

SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed from research at the University of Manchester. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements aimed at modulating the immune system via the gut-skin axis. It has partnerships, such as with Croda plc, and is expanding through acquisitions to enhance its distribution and manufacturing capabilities.

YTD Price Performance: 25.68%

Average Trading Volume: 733,143

Technical Sentiment Signal: Sell

Current Market Cap: £53.93M

Learn more about SBTX stock on TipRanks’ Stock Analysis page.